After hepatitis C cure, companies target next big liver disease market

November 9, 2014 1:07 PM

3 0

NEW YORK (Reuters) - Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.

Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs wil...

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page